Drug Trial Radar · NCT06771115
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
Jan 7, 2025
Primary completion
Sep 10, 2025
Study completion Sep 10, 2025
Sponsor
- Lead sponsor
- Zomagen Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.
Conditions
- Obesity
Interventions
PlaceboDrug
Placebo
VTX3232 30 mgDrug
VTX3232 30 mg
Placebo in combination with semaglutideDrug
Placebo in combination with semaglutide
VTX3232 30 mg in combination with semaglutideDrug
VTX3232 30 mg in combination with semaglutide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)Time frame: From the first dose of study treatment to Week 16
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
840005
Birmingham, Alabama
840003
Lake Forest, California
840011
Long Beach, California
840001
Largo, Florida
840012
Ocoee, Florida
840016
Port Orange, Florida
840014
Newton, Kansas
840015
Marrero, Louisiana
840017
Marrero, Louisiana
840002
Austin, Texas
840006
Dallas, Texas
840013
San Antonio, Texas
840018
San Antonio, Texas
840010
Waco, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.